Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
53
NDRA Quote, Financials, Valuation and Earnings
Last price:
$7.40
Seasonality move
:
-20.79%
Day range:
$7.01 - $7.45
52-week range:
$2.90 - $168.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.82x
P/B ratio:
3.14x
Volume:
92.1K
Avg. volume:
3.3M
1-year change:
-95.21%
Market cap:
$5.5M
Revenue:
--
EPS (TTM):
-$483.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NDRA
ENDRA Life Sciences
|
-- | -$2.27 | -- | -97.63% | $46.00 |
|
BSGM
BioSig Technologies
|
-- | -$0.04 | -100% | -83.33% | $10.00 |
|
ELMD
Electromed
|
$16.4M | -- | 12.26% | -- | $33.50 |
|
IRIX
IRIDEX
|
$12.8M | -$0.12 | -2.72% | -18.18% | -- |
|
MYO
Myomo
|
$9.1M | -$0.11 | 21.62% | -253.33% | $8.70 |
|
STXS
Stereotaxis
|
$7.8M | -$0.07 | 72.15% | -3.57% | $4.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NDRA
ENDRA Life Sciences
|
$7.45 | $46.00 | $5.5M | -- | $0.00 | 0% | 5.82x |
|
BSGM
BioSig Technologies
|
$4.75 | $10.00 | $129.6M | -- | $0.00 | 0% | 172.76x |
|
ELMD
Electromed
|
$18.65 | $33.50 | $156.4M | 23.61x | $0.00 | 0% | 2.72x |
|
IRIX
IRIDEX
|
$1.29 | -- | $21.7M | -- | $0.00 | 0% | 0.44x |
|
MYO
Myomo
|
$2.05 | $8.70 | $73.8M | -- | $0.00 | 0% | 2.07x |
|
STXS
Stereotaxis
|
$2.38 | $4.50 | $204.7M | -- | $0.00 | 0% | 7.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NDRA
ENDRA Life Sciences
|
-- | -4.726 | -- | -- |
|
BSGM
BioSig Technologies
|
-- | 16.724 | 1.94% | 0.75x |
|
ELMD
Electromed
|
-- | 2.259 | -- | 4.79x |
|
IRIX
IRIDEX
|
81.05% | 1.324 | 21.92% | 1.11x |
|
MYO
Myomo
|
-- | -0.171 | -- | 2.24x |
|
STXS
Stereotaxis
|
-- | 2.022 | -- | 0.62x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NDRA
ENDRA Life Sciences
|
-- | -$1.5M | -- | -- | -- | -$1.3M |
|
BSGM
BioSig Technologies
|
-- | -$3M | -- | -- | -30046.15% | -$1.1M |
|
ELMD
Electromed
|
$12.2M | $2.1M | 16.57% | 16.57% | 13.65% | $2.2M |
|
IRIX
IRIDEX
|
$5.1M | -$205K | -140.14% | -218.69% | -1.72% | -$1.2M |
|
MYO
Myomo
|
$6.6M | -$3.5M | -38.11% | -38.11% | -35.81% | -$3.3M |
|
STXS
Stereotaxis
|
$4.1M | -$5.9M | -174.6% | -174.6% | -79.35% | -$1.8M |
ENDRA Life Sciences vs. Competitors
-
Which has Higher Returns NDRA or BSGM?
BioSig Technologies has a net margin of -- compared to ENDRA Life Sciences's net margin of -30115.39%. ENDRA Life Sciences's return on equity of -- beat BioSig Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences-- -$1.86 -- BSGMBioSig Technologies-- -$0.14 $116K -
What do Analysts Say About NDRA or BSGM?
ENDRA Life Sciences has a consensus price target of $46.00, signalling upside risk potential of 517.45%. On the other hand BioSig Technologies has an analysts' consensus of $10.00 which suggests that it could grow by 110.53%. Given that ENDRA Life Sciences has higher upside potential than BioSig Technologies, analysts believe ENDRA Life Sciences is more attractive than BioSig Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences1 0 0 BSGMBioSig Technologies1 0 0 -
Is NDRA or BSGM More Risky?
ENDRA Life Sciences has a beta of -0.178, which suggesting that the stock is 117.84% less volatile than S&P 500. In comparison BioSig Technologies has a beta of 1.706, suggesting its more volatile than the S&P 500 by 70.624%.
-
Which is a Better Dividend Stock NDRA or BSGM?
ENDRA Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioSig Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences pays -- of its earnings as a dividend. BioSig Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or BSGM?
ENDRA Life Sciences quarterly revenues are --, which are smaller than BioSig Technologies quarterly revenues of $13K. ENDRA Life Sciences's net income of -$1M is higher than BioSig Technologies's net income of -$2.8M. Notably, ENDRA Life Sciences's price-to-earnings ratio is -- while BioSig Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences is 5.82x versus 172.76x for BioSig Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences5.82x -- -- -$1M BSGMBioSig Technologies172.76x -- $13K -$2.8M
-
Which has Higher Returns NDRA or ELMD?
Electromed has a net margin of -- compared to ENDRA Life Sciences's net margin of 12.06%. ENDRA Life Sciences's return on equity of -- beat Electromed's return on equity of 16.57%.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences-- -$1.86 -- ELMDElectromed77.97% $0.21 $43.9M -
What do Analysts Say About NDRA or ELMD?
ENDRA Life Sciences has a consensus price target of $46.00, signalling upside risk potential of 517.45%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 79.63%. Given that ENDRA Life Sciences has higher upside potential than Electromed, analysts believe ENDRA Life Sciences is more attractive than Electromed.
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences1 0 0 ELMDElectromed2 0 0 -
Is NDRA or ELMD More Risky?
ENDRA Life Sciences has a beta of -0.178, which suggesting that the stock is 117.84% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.
-
Which is a Better Dividend Stock NDRA or ELMD?
ENDRA Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or ELMD?
ENDRA Life Sciences quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. ENDRA Life Sciences's net income of -$1M is lower than Electromed's net income of $1.9M. Notably, ENDRA Life Sciences's price-to-earnings ratio is -- while Electromed's PE ratio is 23.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences is 5.82x versus 2.72x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences5.82x -- -- -$1M ELMDElectromed2.72x 23.61x $15.7M $1.9M
-
Which has Higher Returns NDRA or IRIX?
IRIDEX has a net margin of -- compared to ENDRA Life Sciences's net margin of -14.17%. ENDRA Life Sciences's return on equity of -- beat IRIDEX's return on equity of -218.69%.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences-- -$1.86 -- IRIXIRIDEX42.49% -$0.10 $4.5M -
What do Analysts Say About NDRA or IRIX?
ENDRA Life Sciences has a consensus price target of $46.00, signalling upside risk potential of 517.45%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 55.04%. Given that ENDRA Life Sciences has higher upside potential than IRIDEX, analysts believe ENDRA Life Sciences is more attractive than IRIDEX.
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences1 0 0 IRIXIRIDEX0 0 0 -
Is NDRA or IRIX More Risky?
ENDRA Life Sciences has a beta of -0.178, which suggesting that the stock is 117.84% less volatile than S&P 500. In comparison IRIDEX has a beta of 0.566, suggesting its less volatile than the S&P 500 by 43.407%.
-
Which is a Better Dividend Stock NDRA or IRIX?
ENDRA Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or IRIX?
ENDRA Life Sciences quarterly revenues are --, which are smaller than IRIDEX quarterly revenues of $11.9M. ENDRA Life Sciences's net income of -$1M is higher than IRIDEX's net income of -$1.7M. Notably, ENDRA Life Sciences's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences is 5.82x versus 0.44x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences5.82x -- -- -$1M IRIXIRIDEX0.44x -- $11.9M -$1.7M
-
Which has Higher Returns NDRA or MYO?
Myomo has a net margin of -- compared to ENDRA Life Sciences's net margin of -35.24%. ENDRA Life Sciences's return on equity of -- beat Myomo's return on equity of -38.11%.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences-- -$1.86 -- MYOMyomo67.23% -$0.08 $21.7M -
What do Analysts Say About NDRA or MYO?
ENDRA Life Sciences has a consensus price target of $46.00, signalling upside risk potential of 517.45%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 324.39%. Given that ENDRA Life Sciences has higher upside potential than Myomo, analysts believe ENDRA Life Sciences is more attractive than Myomo.
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences1 0 0 MYOMyomo3 0 0 -
Is NDRA or MYO More Risky?
ENDRA Life Sciences has a beta of -0.178, which suggesting that the stock is 117.84% less volatile than S&P 500. In comparison Myomo has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.863%.
-
Which is a Better Dividend Stock NDRA or MYO?
ENDRA Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or MYO?
ENDRA Life Sciences quarterly revenues are --, which are smaller than Myomo quarterly revenues of $9.8M. ENDRA Life Sciences's net income of -$1M is higher than Myomo's net income of -$3.5M. Notably, ENDRA Life Sciences's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences is 5.82x versus 2.07x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences5.82x -- -- -$1M MYOMyomo2.07x -- $9.8M -$3.5M
-
Which has Higher Returns NDRA or STXS?
Stereotaxis has a net margin of -- compared to ENDRA Life Sciences's net margin of -77.93%. ENDRA Life Sciences's return on equity of -- beat Stereotaxis's return on equity of -174.6%.
Company Gross Margin Earnings Per Share Invested Capital NDRAENDRA Life Sciences-- -$1.86 -- STXSStereotaxis54.39% -$0.07 $8.2M -
What do Analysts Say About NDRA or STXS?
ENDRA Life Sciences has a consensus price target of $46.00, signalling upside risk potential of 517.45%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 89.08%. Given that ENDRA Life Sciences has higher upside potential than Stereotaxis, analysts believe ENDRA Life Sciences is more attractive than Stereotaxis.
Company Buy Ratings Hold Ratings Sell Ratings NDRAENDRA Life Sciences1 0 0 STXSStereotaxis2 0 0 -
Is NDRA or STXS More Risky?
ENDRA Life Sciences has a beta of -0.178, which suggesting that the stock is 117.84% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.440, suggesting its more volatile than the S&P 500 by 43.964%.
-
Which is a Better Dividend Stock NDRA or STXS?
ENDRA Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ENDRA Life Sciences pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NDRA or STXS?
ENDRA Life Sciences quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $7.5M. ENDRA Life Sciences's net income of -$1M is higher than Stereotaxis's net income of -$5.8M. Notably, ENDRA Life Sciences's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ENDRA Life Sciences is 5.82x versus 7.46x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NDRAENDRA Life Sciences5.82x -- -- -$1M STXSStereotaxis7.46x -- $7.5M -$5.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 13.2% over the past day.
